Due to recent changes in the public account push mechanism, we welcome you to set Boom Health as a 🌟”Starred”🌟 account on the homepage to receive the latest trends and expert insights in the digital healthcare industry! This article is approximately 4300 words long and will take about 10 minutes to read. On April 10, … Read more
Company Overview MediLink Therapeutics was founded in 2020, headquartered in Suzhou (with a research branch in Boston, USA), and has established research institutions in Shanghai and Singapore. The company’s founder, Dr. Xue Tongtong, previously served as the general manager of Kelun-Biotech and has over 10 years of experience in the research and management of antibodies, … Read more
At this year’s AACR annual meeting, there were hundreds of details related to ADC drugs. Leading ADC company Daiichi Sankyo announced the latest research progress of its HER3-targeted ADC product Patritumab deruxtecan (HER3-DXd); AstraZeneca also disclosed research updates on several drugs including AZD9592 (bispecific ADC) and AZD5335 (FRα ADC). Many Chinese pharmaceutical companies also showcased … Read more
This year, CED released the draft for “Technical Guidelines for Non-Clinical Research of Antibody-Drug Conjugates” to assist companies in conducting non-clinical research on ADCs.It provides guidance on non-clinical studies such as “pharmacology, safety pharmacology, pharmacokinetics, and toxicology.”(1) PharmacologyIn the early development of ADCs, studies on the in vitro and in vivo pharmacological/efficacy effects of ADCs … Read more
This article has a total of2229words, reading time:3-4 minutes ｜Author: MaxTom On May 29, 2025, Merck and Daiichi Sankyo jointly announced thevoluntary withdrawal of the market application for the HER3-targeted antibody-drug conjugate (ADC), Patritumab deruxtecan (HER3-DXd), which was originally seeking accelerated approval for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who … Read more
1. Overview of ADC Drugs Antibody-drug conjugates (ADCs) are referred to as the ‘magic bullets’ for cancer treatment. They are a new type of biotherapeutic drug that combines monoclonal antibodies with cytotoxic drugs through a chemical linker. The core concept is to combine the specific targeting ability of antibodies with the powerful killing effect of … Read more
Special Reminder Due to adjustments in the WeChat public account mechanism, please click on the top “Instrument Information Network” → the upper right “…” → set as★ a star, otherwise you may not see our updates. On June 12, XtalPi Technology (XtalPi Holdings, 2228.HK) announced the completion of its acquisition of the UK-based LiverpoolChiroChem (LCC) … Read more
Click the blue text Follow us This Issue Focus Point B7-H4 is a member of the B7 immune checkpoint ligand family, which has been shown to bind to an unknown receptor on T cells, inhibiting T cell proliferation and cytokine production, thereby negatively regulating T cell function. The expression level of B7-H4 is elevated in … Read more
Not all long-established ADC Biotechs can achieve a successful exit like Seagen (Seattle Genetics). Today, Mersana Therapeutics, a 23-year-old veteran biotech, has reached its most desperate moment. With a cumulative deficit of $900 million and only $134.6 million left in cash, its two core pipeline products are still in Phase I clinical trials. To sustain … Read more
Click the “blue text” to follow us Every year, millions of patients worldwide are waiting for organ transplants, but there is a severe shortage of donated organs. Statistics show that in the United States alone, about 20 people die each day waiting for a suitable organ. Faced with this dilemma, scientists have proposed a bold … Read more